Oral small molecules
Also Clin2 multiple neutropenias, Clin1b Waldenstrom's macroglobulinemia; X4P-002 Clin0 oncology; X4P-003 Clin0 neutropenic disorder
X4 Pharmaceuticals is developing novel small molecule therapies that target the X4 receptor. The X4 receptor is a G protein-coupled receptor (GPCR) that plays a key role in the inflammatory response. When the X4 receptor is activated, it signals for the recruitment of leukocytes, which are white blood cells that help to fight infection and repair damaged tissue. However, overactivation of the X4 receptor can lead to chronic inflammation, which is associated with a variety of diseases, including fibrosis. X4 Pharmaceuticals' X4 receptor modulators are designed to selectively modulate the X4 receptor to reduce inflammation and fibrosis without causing unwanted side effects.